NuCana plc is working on some hypotheses about why its Phase II NuTide:323 study of NUC-3373 in colorectal cancer was unsuccessful, including prognostic factors in the study arm versus the control arm or the combination with one of the chemotherapy agents. But the culprit does not appear to be NUC-3373 itself.
NuCana Investigates Why Colorectal Cancer Study Failed
Patients in the NUC-3373 arm had a worse prognosis than those in the control arm, but the company is looking at the combination with irinotecan as the potential culprit.
More from Clinical Trials
• By
The triple therapy improves lung function in the Phase III KALOS and LOGOS studies
• By
DIA Korea hears how multiple domestic and global factors are affecting the environment for clinical trials in South Korea, and what actions may be taken to address this.
• By
On its Q1 earnings call, Moderna avoided criticizing policy changes affecting vaccines but de-emphasized its flu/COVID-19 vaccine for under-50 and prioritized cancer programs.
• By
As the PDUFA date for the UK major’s IL-5 inhibitor draws close.